Last reviewed · How we verify
Homozygous Familial Hypercholesterolemia
Approved treatments
- Caduet · Pfizer Inc.
Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle. - EVKEEZA · REGENERON PHARMACEUTICALS
- Evkeeza · Regeneron
Evkeeza works by blocking the action of Angiopoietin-related protein 3, a protein that helps regulate cholesterol levels in the blood.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Homozygous Familial Hypercholesterolemia patent landscape — cliff calendar, originator estates, attackable patents
- Homozygous Familial Hypercholesterolemia treatment landscape brief
- Homozygous Familial Hypercholesterolemia treatment updates RSS
Frequently asked questions about Homozygous Familial Hypercholesterolemia
What drugs treat Homozygous Familial Hypercholesterolemia?
Tracked treatments include Caduet, EVKEEZA, Evkeeza.
What is the treatment for Homozygous Familial Hypercholesterolemia?
Standard treatment for Homozygous Familial Hypercholesterolemia includes Caduet, EVKEEZA, Evkeeza. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Homozygous Familial Hypercholesterolemia patent cliff · Homozygous Familial Hypercholesterolemia CI report
- Treatment: Caduet · Pfizer Inc.
- Treatment: EVKEEZA · REGENERON PHARMACEUTICALS
- Treatment: Evkeeza · Regeneron
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing